Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Phase

Condition

Primary Immunodeficiency Disorders

Hiv Infections

Treatment

N/A

Clinical Study ID

NCT02711228

IgPro20_4005

2015-004977-34

Ages 5-64
All Genders

Study Summary

The purpose of the study is to assess the impact of immunoglobulin treatment by subcutaneous injections every 2 weeks (biweekly) on a cohort of patients with primary and secondary immune deficiencies. The full study will consist of safety, efficacy and Quality of Life (QoL) evaluations and a pharmacokinetic (PK) sub-study. The primary objectives of the study are to determine tolerability and safety of biweekly IgPro20 injection regimen and to compare PK outcomes on weekly and biweekly IgPro20 therapy.

Patients who have received and/or are currently receiving immunoglobulin G (IgG) in intravenous (IVIg), or subcutaneous (SCIg) infusions are eligible for inclusion if they meet inclusion/exclusion criteria.

The study consists of two parts. In Part 1 of the study enrolled subjects will receive IgPro20 weekly for either 12 weeks (for patients on SCIg infusion prior to the study) or 24 weeks (for patients on IVIg infusion prior to the study). Part 2 will consist of a biweekly treatment with IgPro20 for 52 weeks, for both groups.

Additionally, study subjects meeting inclusion criteria for the PK sub-study will undergo a PK sample collection for 1 week and 2 weeks in study Parts 1 and 2, respectively.

Eligibility Criteria

Inclusion

Inclusion Criteria: Full study:

Female or male patients with primary or secondary immunodeficiency, aged from 5 to 64years, receiving steady state immunoglobulin G replacement therapy. Pharmacokinetic sub-study:
Female or male patients with primary immunodeficiency, aged between 12 and 64 years ofage, on steady-state IgPro20 replacement therapy and willing to undergopharmacokinetic sample collection on weekly and biweekly IgPro20 dosing regimens.

Exclusion

Exclusion Criteria:

Patients with protein losing conditions such as: lymphangiectasis, nephrosis, statuspost cardio-thoracic surgery requiring drainage tubes for more than 48 hours,protein-losing enteropathy.
Concomitant treatment with plasma or other blood products (including any IgGs otherthan IgPro20 [Hizentra]) within 21 days before study entry and/or during the study.
Any other condition or treatment that, in the opinion of the investigator, wouldinterfere with obtaining valid results for that subject.
Women of childbearing potential with a positive pregnancy test.
Active infection at the time of screening.

Study Design

March 15, 2016

January 30, 2018

Connect with a study center

CHU Sainte-Justine
Montreal, QC H3T 1C4
Canada
Site Not Available
Centre Hospitalier de l'université de Montréal
Montreal, QC H2W 1T7
Canada
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.